Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated. Nonclassical ...

Congenital adrenal hyperplasia is a condition that causes the adrenal glands to produce too much androgen, the male sex hormone. This may result in early puberty and other symptoms.

References: Neurocrine Biosciences announces FDA approval of Crenessity™ (crinecerfont), a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia.

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH ...

Study shows crinecerfont aids patients with congenital adrenal hyperplasia. Crinecerfont results in a greater decrease from baseline in the mean daily glucocorticoid dose among patients with ...

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to ...

Orlando, Florida — New data add to the evidence supporting use of crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, in both adults and ...

Learn about a new drug for classic congenital adrenal hyperplasia (CAH). A top expert explains crinecerfont and its benefits, how it works, and its impact on CAH treatment.

CRF1 receptor antagonists in congenital adrenal hyperplasia: A systematic review and meta-analysis of phase 2 open-label and phase 3 clinical trials, Endocrine and Metabolic Science, 18, (100247 ...